Hepatitis b drug showdown: which is safer for kidneys?
NCT ID NCT03933384
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two antiviral drugs, tenofovir alafenamide (TAF) and entecavir, in 140 adults with chronic hepatitis B. The goal is to see which one controls the virus better and causes fewer kidney problems. Participants take one pill daily for about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tenofovir alafenamide (TAF) and entecavir
- What this could lead to
- If successful, this could show that TAF is as effective as entecavir at suppressing hepatitis B virus, with better kidney safety.
- What could go wrong
- This is a relatively small, open-label trial (not blinded), so results may be less reliable. Both drugs are already approved; the study compares them rather than testing a new cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taichung Veterans General Hospital
RECRUITINGTaichung, Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple roadside test catch liver disease before it turns deadly?
- Hospital care model aims to treat opioid addiction and serious infections together
- Simple blood test aims to spot multiple cancers early
- Heart safety check for hepatitis b drug candidate
- Two-Drug combo aims to cure chronic hepatitis b
- Hepatitis b breakthrough? study checks if bepirovirsen response lasts